Table 2.

Clinical characteristics of the study population

Indicators	Value
Age (years)	47.27±13.61
Sex (male/female)	45/6
BMI (kg/m2)	22.78±2.61
AEtiology of chronic liver disease, n, (%)
HBV	45 (88.2)
HCV	0
Alcoholic hepatitis	4 (7.8)
Drug induced liver injury	0
Autoimmune hepatitis	0
Wilson’s disease	4 (7.8)
Other causes	0
Prognostic score before liver transplantation
MELD score	34.90±5.61 (21–41)
MELD ≤ 9	0
MELD 10–19	0
MELD 20–29	9 (17.65)
MELD 30–39	25 (49.02)
MELD ≥40	17 (33.33)
Average ACLF grade	2.12±0.55 (1–3)
ACLF grade I	5 (9.8)
ACLF grade II	35 (68.6)
ACLF grade III	11 (21.6)
Average AARC score	9.43±1.68 (6–13)
Preoperative laboratory data
Platelets (G/l)	84.33±44.18
PT (%)	38.24±16.11
INR	2.36±1.04
Lactate (mmol/l)	2.87±2.51
GOT (AST) (U/l)	202.03±174.89
GPT (ALT) (U/l)	149.99 ±162.15
GGT (U/l)	61.56±46.78
Serum albumin (g/l)	33.13 ±4.18
Serum total bilirubin (micromol/l)	362.33 ±163.22
Serum creatinine (micromol/l)	90.18±±63.03
Morbidity before liver transplantation
Hepatic encephalopathy, n (%)	19 (37.25)
Grade I, n (%)	3 (5.88)
Grade II, n (%)	5 (9.80)
Grade III, n (%)	4 (7.84)
Grade IV, n (%)	7 (13.73)
Hepatorenal syndrome, n (%)	7 (13.73)
Infection, n (%)	9 (17.65)
The number of patients that require PEX, n (%)	36 (70.6)
Average number of times (n=36)	3.28±2.75
CMV infected, n (%)	7 (13.73)

AARC, The APASL ACLF Research Consortium; ACLF, acute-on-chronic liver failure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CMV, cytomegalovirus; GGT, gamma-glutamyl transferase; GOT, glutamic oxaloacetic transaminase; GPT, glutamate pyruvate transaminase; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; MELD, model for end-stage liver disease; PEX, plasma exchange; PT, prothrombin time.